ES2337005B1 - COMPOUNDS OF PIRAZOLINA AZEPAN OR AZOCANSUSTITUIDOS, ITS PREPARATION AND ITS USE AS MEDICINES. - Google Patents

Abstract

Pyrazoline compounds azepan o azocansustituidos, its preparation and its use as medicines.

The present invention relates to compounds of pyrazoline azepan or azocansubstituted, procedures for its preparation, medicines comprising these compounds as well as its use for the preparation of a medication for the treatment of human beings and animals

Description

Pyrazoline compounds azepan o azocansustituidos, its preparation and its use as medicines.

The present invention relates to compounds of pyrazoline azepan or azocansubstituted, procedures for its preparation, medicines comprising these compounds as well as its use for the preparation of a medicine for the treatment of human beings and animals

       \ vskip1.000000 \ baselineskip
    

Field of the Invention

The present invention relates to compounds of pyrazoline azepan or azocansubstituted, methods for its preparation, medicines comprising these compounds, in addition to their use for the preparation of a medicine for the treatment of beings humans and animals

       \ vskip1.000000 \ baselineskip
    

Background of the invention

Cannabinoids are compounds that are derived from the Cannabis sativa plant that is commonly known as marijuana. The most active chemical compound of natural cannabinoids is tetrahydrocannabinol (THC), particularly Δ9 -THC.

These natural cannabinoids, in addition to their synthetic analogs, enhance their physiological effects through of binding to specific G-protein coupled receptors, the called cannabinoid receptors.

Currently, they have been identified and cloned two different types of receptors that bind both to natural cannabinoids as synthetic. These receivers, which CB_ {1} and CB_ {2} are designated, participate in a variety of physiological or pathophysiological processes in humans and animals, for example, system related processes central nervous, the immune system, the cardiovascular system,  the endocrine system, the respiratory system, the tract gastrointestinal or with reproduction, as described by example, in Hollister, Pharm. Rev. 38, 1986, 1-20; Reny and Singha, Prog. Drug. Res., 36, 71-114, 1991; Consroe and Sandyk, in Marijuana / Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L. and Barthe A. Eds., CRC Press, 1992.

Therefore, compounds that have a high binding affinity for these cannabinoid receptors and that are suitable for modulating these receptors are useful in prevention and / or treatment of disorders related to recipients of cannabinoids

In particular, the CB_ {1} receiver participates in many different disorders related to ingestion of foods, such as bulimia or obesity, including obesity associated with type II diabetes (non-insulin dependent diabetes) and therefore, suitable compounds can be used to regulate this receptor in the prophylaxis and / or treatment of these disorders.

       \ vskip1.000000 \ baselineskip
    

Description of the invention

An object of the present invention was provide novel compounds for use as principles Medication assets In particular, these active ingredients must be suitable for the modulation of the receptors of cannabinoids, more particularly for the modulation of cannabinoid 1 receptors (CB1).

This object was achieved by providing the azepan or azocansubstituted pyrazoline compounds of formula general I given below, its stereoisomers, salts corresponding and corresponding solvates thereof.

It has been found that these compounds have a high affinity for cannabinoid receptors, particularly for the CB1 receptor, and acting as modulators, by example, antagonists, inverse agonists or agonists of these receivers Therefore, they are suitable for prophylaxis and / or treatment of various system related disorders central nervous, the immune system, the cardiovascular system, the endocrine system, the respiratory system, the tract gastrointestinal or with reproduction in humans and / or animals, preferably in humans including infants, Children and seniors.

       \ newpage
    

Therefore, in one of its aspects this invention relates to pyrazoline compounds azepan or azocansubstituted of general formula I,

one

in the that

X and Y independently represent phenyl, thienyl, naphthyl or pyridyl, whose groups may be substituted with 1, 2 or 3 substituents W, which may be the same or different, selected from the group

I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, CHF2, CH 2 F, OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -alkyl C 1-20;

- R 8 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 9 represents

2

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

or

- R 8 and R 9 together with the atom of connection nitrogen represent

3

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing;

in the form shown or in the form of the acid or the base or in the form of a salt, especially a physiologically salt acceptable, or in the form of a solvate, especially a hydrate or in corresponding N-oxide form thereof.

       \ vskip1.000000 \ baselineskip
    

In the context of this invention, it is understood that the alkyl radical or group means saturated and unsaturated, linear or branched hydrocarbons, which may be unsubstituted or monosubstituted or polysubstituted. Thus, "unsaturated alkyl" is understood as comprising alkenyl and alkynyl groups, such as, for example, -CH = CH-CH 3 or -C? -CH 3, while saturated alkyl comprises, for example, - CH 3 and -CH 2 -CH 3. In these radicals, C1-2 alkyl represents C1- or C2- alkyl, C1-3 alkyl represents C1-, C2- or C3 alkyl, C1-4 alkyl represents C1-, C2- alkyl , C3- or C4, C 1-5 alkyl represents C1-, C2-, C3-, C4-, or C5 alkyl, C 1-6 alkyl represents C1-, C2-, C3-, C4- alkyl , C5- or C6, C1-7 alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7 alkyl, C1-8 alkyl represents C1-, C2- alkyl, C3-, C4-, C5-, C6-, C7- or C8-alkyl, C 1-10 alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8 alkyl -, C9- or C10 and C 1-18 alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C11-, C12 alkyl -, C13-, C14-, C15-, C16-, C17- or C18. The alkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propynyl, methyl ethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1,1 -dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, if CHF2, CF3 or CH2OH is also substituted,
etc.

In the context of the invention, it is understood that the radical or cycloalkyl group means cyclic hydrocarbons saturated and unsaturated (but not aromatic) (no heteroatom in the ring), which may be unsubstituted or monosubstituted or polysubstituted In addition, C 3-4 cycloalkyl represents C3- or C4 cycloalkyl, cycloalkyl C 3-5 represents C3-, C4- or cycloalkyl C5-cycloalkyl, cycloalkyl C 3-6 represents C3-, C4-, C5- or cycloalkyl C6, C 3-7 cycloalkyl represents cycloalkyl C3-, C4-, C5-, C6- or C7-, C 3-8 cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8 cycloalkyl, cycloalkyl C 4-5 represents C4- or C5 cycloalkyl, C 4-6 cycloalkyl represents C4- cycloalkyl, C5- or C6, C 4-7 cycloalkyl represents C4-, C5-, C6- or C7 cycloalkyl, C 4-8 represents C4-, C5-, C6-, C7- or C8 cycloalkyl, cycloalkyl C 5-6 represents C5- or C6 cycloalkyl and C 5-7 cycloalkyl represents C5- cycloalkyl, C6- or C7-. However, monounsaturated cycloalkyl or polyunsaturated, preferably monounsaturated, will be inside of the term cycloalkyl as long as the cycloalkyl is not a aromatic system The alkyl and cycloalkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propynyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl.

In relation to the alkyl or aliphatic group - a unless otherwise defined - it is understood that the term substituted in the context of this invention means replacement of at least one hydrogen radical for F, Cl, Br, I, NH2, SH or OH, it is understood that "polysubstituted" radicals means that the substitution takes place in both different and various atoms times in the same atom with the same substituent or with different substituents, for example three times on the same atom of C, as in the case of CF_ {3}, or in different places, as in the case of, for example, -CH (OH) -CH = CH-CHCl2.

It is understood that the term (CH 2) 3-6 means -CH_ {2} -CH_ {2} -CH_ {2} -, -CH 2 -CH 2 -CH 2 -CH 2 -, -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {2} - Y -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {-}  it is understood that (CH2) 1-4 means -CH_ {2} -, -CH_ {2} -CH_ {2} -, -CH_ {2} -CH_ {2} -CH_ {2} - and -CH 2 -CH 2 -CH 2 -CH 2 -, it is understood that (CH2) 4-5 means -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {2} - Y -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {2} -CH_ {2} -, etc.

It is understood that an aryl group or radical means a ring system with at least one aromatic ring but  without heteroatoms even in only one of the rings. The examples they are phenyl, naphthyl, fluorantenyl, fluorenyl, tetralinyl or indanyl, in particular 9H-fluorenyl radicals or anthracenyl, which may be unsubstituted, monosubstituted or polysubstituted

In the context of this invention, it is understood what alkyl-aryl means an aryl group (see above) that is connected to another atom through a group alkyl (see above) (preferably an alkyl C_ {1-4}), while the alkyl is always saturated and linear or branched always refers to alkyl. Between Examples include a benzyl group.

It is understood that a heterocyclyl group or radical means heterocyclic ring systems, saturated or unsaturated, containing one or more heteroatoms in the ring of the group consisting of nitrogen, oxygen and / or sulfur and can also be monosubstituted or polysubstituted. Can be mentioned examples of the heterocyclyl group that are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1,2,5-thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole and quinazoline

In the context of this invention, it is understood what alkyl heterocyclyl means a group heterocyclyl (see above) that is connected to another atom at through an alkyl group (see above) (preferably a C 1-4 alkyl), while alkyl always is saturated and linear or branched always refers to the I rent.

In relation to aryl, alkyl-aryl, cycloalkyl or alkyl-cycloalkyl, heterocyclyl or alkyl-heterocyclyl, substituted is understood - a unless otherwise defined - the replacement of the annular system of the aryl or alkyl-aryl, cycloalkyl or alkylcycloalkyl; heterocyclyl or alkyl-heterocyclyl by OH, SH, = O, halogen (F, Cl, Br, I), CN, NO2, COOH; NHR_ {R} {y}, where R_ {y} is R y, independently, or H or alkyl C_ {1-6} saturated or unsaturated, linear or branched, substituted or unsubstituted; I rent C_ {1-6} saturated or unsaturated, linear or branched, substituted or unsubstituted; -O-alkyl C 1-6 (saturated or unsaturated, alkoxy) linear or branched, substituted or unsubstituted; -S-alkyl C_ {1-6} saturated or unsaturated, linear or branched, substituted or unsubstituted; a group -C (O) -C 1-6 alkyl saturated or unsaturated, linear or branched, substituted or not replaced; a group -C (O) -O-alkyl C_ {1-6} saturated or unsaturated, linear or branched, substituted or unsubstituted; an aryl or substituted or unsubstituted alkyl aryl; a cycloalkyl or substituted or non-substituted alkyl cycloalkyl replaced; a heterocyclyl or alkyl-heterocyclyl substituted or unsubstituted.

It is understood that the term "salt" means any form of active compound used according to the invention in the that an ionic form is assumed or charged and coupled with a counterion (a cation or an anion) or is in solution. Must also understood as complexes of the active compounds with other molecules and ions, in particular complexes that are complexed through ionic interactions.

The term "physiologically acceptable salt" means in the context of this invention any salt that is physiologically tolerated (most of the time means that it is not especially toxic not caused by the counterion) if used properly for a treatment especially if used in , or applies, to humans and / or mamma-
feros

These physiologically acceptable salts can form with cations or bases and it is understood that in the context of this invention means salts of at least one of the compounds used according to the invention - normally an acid (deprotonated) - as an anion with at least one preferably inorganic cation, which it is physiologically tolerated, especially if used on beings humans and / or mammals. Particularly preferred are the salts of alkali and alkaline earth metals, and also those salts of NH4, but in particular (mono) - or (di) sodium salts, (mono) - or (di) potassium, magnesium or calcium.

These physiologically acceptable salts can also be formed with anions or acids it is understood that in the context of this invention mean salts of at least one of the compounds used according to the invention - normally protonated, by example in nitrogen- like the cation with at least one anion that Physiologically tolerate - especially if used on beings humans and / or mammals. It is understood by this, in particular, in the context of this invention, the salt formed with a tolerated acid physiologically, ie salts of the particular active compound with organic and inorganic acids that are physiologically tolerated especially if used in humans and / or mammals. Examples of physiologically tolerated salts of particular acids are salts  of hydrochloric acid, hydrobromic acid, sulfuric acid, acid methanesulfonic acid, formic acid, acetic acid, oxalic acid, acid succinic, malic acid, tartaric acid, mandelic acid, acid fumaric, lactic acid or citric acid.

The compounds of the present invention can be in crystalline form or as free compounds or as solvates and it is intended that these forms are within the scope of the present invention Solvation methods are generally known in the art. Suitable solvates are solvates pharmaceutically acceptable. It is understood that the term "solvate" according to this invention means any form of active compound according to the invention in which the compound is bound through non-covalent bonds to another molecule (more probably a polar solvent) that especially includes hydrates and alcoholates, for example methanolate.

Unless stated otherwise, the compounds of the invention include compounds that differ only in the presence of one or more atoms enriched in an isotopic manner. By example, compounds having the present structures except by substituting one carbon for 13 C-enriched carbon or 14 C- or enriched nitrogen 15 N are within range of this invention.

The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable form or substantially pure. By pharmaceutically acceptable form it understand, among other things, that it has a level of purity pharmaceutically acceptable excluding pharmaceutical additives normal, such as diluents and carriers, and including the material not considered toxic at normal dosage levels. The purity levels for the drug substance are preferably above 50%, more preferably above 70%, even more preferably above 90%. In a preferred embodiment, is above 95% of the compound of formula (I), or, of its salts, solvates or prodrugs.

       \ newpage
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention are of general formulas Ia or Ib

4

in the that

X and Y independently represent phenyl, thienyl, naphthyl or pyridyl, whose groups may be substituted with 1, 2 or 3 substituents W, which may be the same or different, selected from the group

I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, CHF2, CH 2 F, OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -alkyl C 1-20;

- R 8 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 9 represents

5

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

or

- R 8 and R 9 together with the atom of connection nitrogen represent

6

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate, or in the form of a corresponding N-oxide of the same.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the present invention, azepan or azocansubstituted pyrazoline compounds according to the present invention are of general formula II

7

in the that

R 11, R 12, R 13 and R 14, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, CHF2, CH 2 F, OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

- R 18 represents C 1-3 branched or linear, while R19 represents

8

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2

or

- R 18 and R 19 together with the atom of connection nitrogen represent

9

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing;

in the form shown or in the form of the acid or the base or in the form of a salt, especially a physiologically salt acceptable, or in the form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the present invention, azepan or azocansubstituted pyrazoline compounds according to the present invention they are of general formulas IIa or IIb

10

in the that

R 11, R 12, R 13 and R 14, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, CHF2, CH2F, OCHF2, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group that consists of aryl, C 8-20 alkyl, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

- R 18 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 19 represents

eleven

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2;

or

- R 18 and R 19 together with the atom of connecting nitrogen represent

       \ vskip1.000000 \ baselineskip
    

12

       \ vskip1.000000 \ baselineskip
    

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas II, IIa or IIb is characterize why

R 11, R 12, R 13 and R 14, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

       \ vskip1.000000 \ baselineskip
    

preferably

R 11, R 12, R 13 and R 14, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas II, IIa or IIb is characterize why

R 18 represents H.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas II, IIa or IIb is characterize why

R 15, R 16, and R 17 are selected, independently of each other, from H, F, Cl, Br, I, OH, CH 3, C 2 H 5, OCH 3, OCF 3 or CF 3.

       \ newpage
    

In a preferred embodiment of the present invention, azepan or azocansubstituted pyrazoline compounds according to the present invention they are of general formula III,

13

in the that

R 21, R 22, R 23 and R 24, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

- R 28 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 29 represents

14

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

or

- R 28 and R 29 together with the atom of connecting nitrogen represent

       \ vskip1.000000 \ baselineskip
    

fifteen

       \ vskip1.000000 \ baselineskip
    

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing;

in the form shown or in the form of the acid or the base or in the form of a salt, especially a physiologically salt acceptable, or in the form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the invention are of general formulas IIIa or IIIb,

16

in the that

R 21, R 22, R 23 and R 24, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

- R 28 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 29 represents

17

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

or

- R 28 and R 29 together with the atom of connecting nitrogen represent

18

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the The present invention of general formulas III, IIIa or IIIb is characterize why

R 21 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while

R 22, R 23 and R 24, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

       \ vskip1.000000 \ baselineskip
    

preferably

R 21 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while

R 22, R 23 and R 24, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

       \ vskip1.000000 \ baselineskip
    

more preferably

R 21 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while

R 22, R 23 and R 24, independently of each other, they represent OH, OCH 3, F, Cl, Br, I, or OCF_ {3}.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the The present invention of general formulas III, IIIa or IIIb is characterize why

R 21, R 22, R 23 and R 24, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

       \ vskip1.000000 \ baselineskip
    

preferably

R 21, R 22, R 23 and R 24, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

       \ vskip1.000000 \ baselineskip
    

more preferably

R 21 represents H, while R 22, R 23 and R 24, independently of each other, represent OH, OCH_ {3}, F, Cl, Br, I, or OCF_ {3}.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the The present invention of general formulas III, IIIa or IIIb is characterize why

R 28 represents H.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the The present invention of general formulas III, IIIa or IIIb is characterize why

R 25, R 26 and R 27, independently of each other, they are selected from H, F, Cl, Br, I, OH, CH 3, C 2 H 5, OCH 3, OCF 3, or CF 3.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the The present invention are of general formulas IV, IVa or IVb

19

in the that

R 31, R 32, R 33 and R 34, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

R 35, R 36 and R 37, independently of each other, they are selected from H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2;

R 38 represents a hydrogen atom or a C 1-3 linear or branched group;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention are of general formulas IVc, IVd or IVe,

twenty

in the that

R 31, R 32, R 33 and R 34, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

R 35, R 36 and R 37, independently of each other, they are selected from H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas IV, IVa, IVb, IVc, IVd, IVe are characterized because

R 31 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while

R 32, R 33 and R 34, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

       \ vskip1.000000 \ baselineskip
    

preferably

R 31 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while

R 32, R 33 and R 34, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

       \ vskip1.000000 \ baselineskip
    

more preferably

R 31 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while

R 32, R 33 and R 34, independently of each other, they represent OH, OCH 3, F, Cl, Br, I, or OCF_ {3}.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas IV, IVa, IVb, IVc, IVd, IVe are characterized because

R 31, R 32, R 33 and R 34, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

       \ vskip1.000000 \ baselineskip
    

preferably

R 31, R 32, R 33 and R 34, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

       \ vskip1.000000 \ baselineskip
    

more preferably

R 31 represents H, while R 32, R 33 and R 34, independently of each other, represent OH, OCH_ {3}, F, Cl, Br, I, or OCF_ {3}.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas IV, IVa, IVb, IVc, IVd, IVe are characterized because

R 38 represents H.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas IV, IVa, IVb, IVc, IVd, IVe are characterized because

R 35, R 36 and R 37, independently of each other, they are selected from H, F, Cl, Br, I, OH, CH 3, C 2 H 5, OCH 3, OCF 3, or CF 3.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the invention, the azepan or azocansubstituted pyrazoline compounds according to the present invention of general formulas IV, IVa, IVb, IVc, IVd, IVe They are selected from the group consisting of:

? N- (azepan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

? (R) -N- (azepan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

? (S) -N- (azepan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

? N- (azepan-1-yl) -5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

? N- (azepan-1-yl) -5- (4-fluorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

? N- (azepan-1-yl) -5- (4-methoxyphenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide,

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing;

optionally in the form of an N-oxide corresponding, a corresponding salt or a solvate correspondent.

       \ vskip1.000000 \ baselineskip
    

In a preferred embodiment of the present invention the azepan or azocansubstituted pyrazoline compounds of general formulas IVc, Ivd or Ive according to the present invention, select from the group consisting of:

? (azepan-1-yl) -1- (2,4-dichlorophenyl) -5- (4-chlorophenyl) -4,5-dihydro-1H-pyrazol-3-yl) methanone

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing;

optionally in the form of an N-oxide corresponding, a corresponding salt or a solvate correspondent.

       \ vskip1.000000 \ baselineskip
    

In another aspect the present invention it also provides a procedure for the preparation of substituted pyrazoline compounds of general formula I according to the present invention, wherein at least one benzaldehyde compound of general formula V

twenty-one

in which X has the meaning described above, it is reacted with a compound of general formula pyruvate (SAW)

22

in which G represents an OR group R being a branched C 1-6 alkyl radical or unbranched or G represents a group O - K with K being a cation, to give a compound of general formula (VII)

2. 3

in which X has the meaning mentioned above, which is optionally isolated and / or optionally it is purified, and that is reacted with a optionally substituted phenylhydrazine of the general formula (VIII)

       \ vskip1.000000 \ baselineskip
    

24

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

or a corresponding salt of same, in which Y has the meaning mentioned above, under inert atmosphere, to give a compound of general formula (IX)

       \ vskip1.000000 \ baselineskip
    

25

       \ vskip1.000000 \ baselineskip
    

       \ vskip1.000000 \ baselineskip
    

in which X and Y have the meaning mentioned above, which is optionally isolated and / or optionally purified, and optionally transferred under inert atmosphere to a compound of general formula (XI) through the reaction with an agent activating

       \ vskip1.000000 \ baselineskip
    

26

       \ newpage
    

in which the substituents X and Y they have the meaning mentioned above and A represents a leaving group, said compound being optionally isolated and / or optionally purified, and at least one compound of formula general (XI) is reacted with a compound of formulas general XII or XIIa

27

in which n, R 5, R 6, R 7 and R 8 are as described above; low inert atmosphere to give a substituted pyrazoline compound of general formula I, which is optionally isolated and / or optionally purify

       \ vskip1.000000 \ baselineskip
    

The process of the invention is also illustrated in scheme I, given below:

Scheme one

28

The reaction of the benzaldehyde compound of general formula V with a pyruvate compound of general formula VI is preferably carried out in the presence of at least one base, more preferably in the presence of a metal hydroxide alkali such as sodium hydroxide or potassium hydroxide or a alkali metal methoxide such as sodium methoxide, as describes, for example, in Synthetic communications, 26 (11), 2229-33, (1996). The respective description is included in this document by reference and is part of the description. Preferably sodium pyruvate is used as the pyruvate compound This reaction is carried out. preferably in a protic reaction medium such as an alcohol C 1-4 alkyl or mixtures thereof. I also know they can use mixtures of said alcohols with water, for example, ethanol / water

The reaction temperature as well as the duration of the reaction, it can vary over a wide range. The Preferred reaction temperatures range from -10 ° C to boiling point of the reaction medium. Reaction times suitable may vary, for example, from several minutes to several hours.

Also preferably, the reaction of benzaldehyde compound of general formula V with a compound of pyruvate of general formula VI is carried out under conditions acid catalyzed, more preferably refluxing the dichloromethane mixture in the presence of trifluoromethanesulfonate of copper (II) as described, for example, in Synlett, (1), 147-149, 2001. The respective description is included in this document as a reference and is part of the description.

The reaction of the compound of the general formula (VII) with an optionally substituted phenylhydrazine of the formula general (VIII) is preferably carried out in a medium of suitable reaction such as alcohols or ethers C 1-4 such as dioxane or tetrahydrofuran or mixtures of at least two of these mentioned compounds previously. Also preferably, said reaction can carried out in the presence of an acid, in which the acid can be organic, such as acetic and / or inorganic acid such as acid hydrochloric. In addition, the reaction can also be carried out in presence of a base such as piperidine, pierazine, hydroxide sodium, potassium hydroxide, sodium methoxide or sodium ethoxide, or A mixture of at least two of these bases may also be used.

The reaction temperature as well as the Reaction duration may vary over a wide range. The suitable reaction temperatures range from temperature ambient, that is, approximately 25 ° C to the point of boiling of the reaction medium. Adequate reaction times they can vary, for example, from several minutes to several hours.

The carboxylic group of the compound of formula general (VIII) can be activated for additional reactions by the introduction of a suitable leaving group according to methods Conventionals well known to those skilled in the art. Preferably, the compounds of general formula (IX) are transferred into an acid chloride, a mixed anhydride, a C 1-4 alkyl ester, an activated ester such as p-nitrophenyl ester. Other methods well Known for acid activation include activation with N, N-dicyclohexylcarbodiimide or hexafluorophosphate benzotriazol-N-oxotris (dimethylamino) phosphonium (BOP)

If said activated compound of general formula (XI) is an acid chloride, preferably prepared by reaction of the corresponding acid of general formula (IX) with thionyl chloride or oxalyl chloride, wherein said Chlorination is also used as the solvent. Can also be used preferably an additional solvent. Suitable solvents include hydrocarbons such as benzene, toluene or xylene, halogenated hydrocarbons such as dichloromethane, chloroform or carbon tetrachloride, ethers such as diethyl ether, dioxane, tetrahydrofuran or dimethoxyethane. Mixtures of two or more solvents of one class or two or more solvents of different classes The preferred reaction temperature has a range from 0 ° C to the boiling point of the solvent and reaction times from several minutes to several hours.

If said activated compound of general formula (XI) is a mixed anhydride, said anhydride can be prepared preferably, for example, by reaction of the acid of formula general (IX) corresponding with ethyl chloroformate in presence of a base such as triethylamine or pyridine, in a suitable solvent.

The reactions mentioned above that involve the synthesis of the 4,5-dihydropyrazole ring or the reaction of a compound comprising said ring are brought to conducted in an inert atmosphere, preferably nitrogen or argon, to prevent oxidation of the annular system.

During the procedures described previously it may be necessary and / or desirable to protect sensitive groups or reagents. The introduction of groups groups conventional protectors, as well as their removal, can be carry out by methods known to experts in the matter.

If the pyrazoline compounds themselves azepan or azocansubstituted of general formula I are obtained in the form of a mixture of stereoisomers, in particular enantiomers or diastereomers, said mixtures can be separated by procedures customary used by those skilled in the art, for example, Chromatographic methods or crystallization with chiral reagents. It is also possible to obtain pure stereoisomers through the stereoselective synthesis.

In a further aspect the present invention it also provides a process for the preparation of salts of substituted pyrazoline compounds of general formula I and stereoisomers thereof, in which at least one compound of general formula I that has at least one basic group is made react with at least one organic and / or inorganic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media include, for example, any of those provided above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, suitable organic acids are, by example, citric acid, maleic acid, fumaric acid, acid tartaric acid, or derivatives thereof, acid p-toluenesulfonic acid, methanesulfonic acid or acid camphorsulfonic.

In yet another additional aspect the present invention also provides a process for the preparation of salts of azepan or azocansubstituted pyrazoline compounds of general formula I or stereoisomers thereof, in which at less a compound of general formula I with at least one acidic group it is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium. The right bases they are, for example, hydroxides, carbonates or alkoxides, which include suitable cations, derived, for example, from alkali metals, alkaline earth metals or organic cations, for example [NH_ {n} R_-4] +, where n is 0, 1, 2, 3 or 4 and R represents an alkyl radical C 1-4 branched or unbranched. The means of Suitable reactions are, for example, any of those provided previously.

You can also get solvates, preferably hydrates, of the compounds of pyrazoline azepan or azocansubstituted of general formula I, of the corresponding stereoisomers, of the corresponding N-oxides or of the corresponding salts thereof by procedures customary known to those skilled in the art.

Compounds of substituted pyrazoline of general formula I, comprising rings,  saturated, unsaturated or aromatic containing an atom of nitrogen in the form of its N-oxides by well methods known to those skilled in the art.

Those skilled in the art understand that the term substituted pyrazoline compounds as used in the present invention is understood to also comprise derivatives, such as ethers, esters and complexes of these compounds. The term "derivatives" as used in the application is defined herein as meaning a chemical compound that has undergone a process of derivation from an active compound to change (improve for pharmaceutical use) any of its physicochemical properties. , especially a so-called prodrug, for example, its esters and ethers. Examples of well known methods for producing a prodrug of a given active compound are known to those skilled in the art and can be found, for example, in Krogsgaard-Larsen et al ., Textbook of Drugdesign and Discovery, Taylor & Francis (April 2002) . The respective description is incorporated herein by reference and is part of the description.

The purification and isolation of substituted pyrazoline compounds of general formula I of the invention of a corresponding stereoisomer, or salt, or N-oxide, or solvate or any intermediate thereof be carried out, if desired, by conventional methods known to those skilled in the art, for example, methods chromatographic or recrystallization.

Pyrazoline compounds azepan or azocansubstituted general formula I provided above, their  stereoisomers, the corresponding N-oxides, the corresponding salts thereof and the corresponding Solvates are toxicologically acceptable and therefore suitable as pharmaceutical active ingredients for the preparation of medicines.

It has been found that the compounds of pyrazoline azepan or substituted azocans of general formula I provided above, stereoisomers thereof, N-oxides thereof, the corresponding salts and corresponding solvates have a high affinity for the receptors of cannabinoids, particularly cannabinoid receptors 1 (CB1), that is, are selective ligands for the receptor CB1 and act as modulators, for example antagonists, Inverse agonists or agonists, in these receptors. In particular, these substituted pyrazoline compounds show little or no tolerance development during treatment, particularly with regarding food intake, that is, if the treatment it is interrupted for a period of time and then continued subsequently, the pyrazoline compounds used according to the invention will again show the desired effect. After finishing the treatment with pyrazoline compounds, it is found that The positive influence on body weight continues.

In addition, these compounds of pyrazoline azepan or azocansubstituted show an affinity for the Herg channel relatively weak, therefore, for these compounds an expected low risk of prolongation of the QT interval.

In short, pyrazoline compounds 4-substituted according to the invention are distinguished by a broad spectrum of beneficial effects while at the same time show relatively few unwanted effects, that is, effects that do not contribute positively to or that even interfere with the patient's well-being.

Therefore, another aspect of the present invention refers to a medicament comprising at least one compound of azepan or azocansubstituted pyrazoline of general formula I, optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixture, or a corresponding N-oxide thereof, or a salt physiologically acceptable thereof, or a solvate corresponding thereof, and optionally at least one agent Physiologically acceptable auxiliary.

Preferably said medicament is suitable. for the modulation (regulation) of cannabinoid receptors, preferably of the cannabinoid 1 (CB1) receptors, for the prophylaxis and / or treatment of system disorders central nervous, immune system disorders, disorders of the cardiovascular system, disorders of the endocrine system, respiratory system disorders, tract disorders gastrointestinal or reproductive disorders.

Particularly, preferably said medication is suitable for prophylaxis and / or treatment of psychosis.

In addition, particularly preferably said medication is suitable for prophylaxis and / or treatment of eating disorders, preferably bulimia, anorexia, cachexia, obesity and / or diabetes mellitus type II (non-insulin dependent diabetes). The medicament of the invention It also appears to be active in the prophylaxis and / or treatment of appetite disorders, for example, pyrazolines compounds of general formula I also reduce the desire to eat sweets.

In addition, particularly preferably said medication is suitable for prophylaxis and / or treatment of cancer, preferably for the prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, liver cancer, cancer bladder, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, intestinal cancer and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of colon cancer, cancer Intestinal and prostate cancer.

Particularly preferably said medication is suitable for prophylaxis and / or treatment of alcoholism and / or alcohol addiction, nicotine abuse and / or smoking, drug abuse and / or drug addiction and / or drug abuse and / or drug dependence, preferably drug abuse and / or drug addiction and / or abuse of nicotine and / or smoking.

Medications / drugs, which are frequently subject to abuse include opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines.

The medicine is also suitable for prophylaxis and / or treatment of one or more of the disorders selected from the group consisting of bone disorders, preferably osteoporosis (for example, associated osteoporosis with a genetic predisposition, sex hormone deficit or aging), bone disease associated with cancer or disease Paget's bone; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, disorders spinocerebellar, cognitive disorders, head trauma, head trauma, stroke, seizures panic, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, Huntington's disease, Alzheimer's disease, Raynaud's disease, tremors, disorders compulsive, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, movement disorders induced by medications, dystonia, endotoxémic shock, hemorrhagic shock, hypotension, insomnia, immune disorders, plaques sclera, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for the potentiation of the analgesic effect of narcotic and non-narcotic pain relievers, or to influence the intestinal transit.

Another aspect of the present invention is the use of at least one azepan or azocansubstituted pyrazoline compound of general formula I previously provided as active ingredients, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixture, or a corresponding N-oxide thereof, or a salt corresponding thereof, or a corresponding solvate of the themselves, and optionally one or more pharmaceutically excipients acceptable, for the preparation of a medicine for cannabinoid receptor modulation, preferably cannabinoid 1 (CB1) receptors, for prophylaxis and / or treatment of central nervous system disorders, disorders of the immune system, disorders of the cardiovascular system, endocrine system disorders, system disorders respiratory, gastrointestinal tract disorders or disorders players.

Particularly preferred is the use of at least one of the respective compounds of pyrazoline azepan or azocansubstituted, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof, and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicine for the prophylaxis and / or treatment of psychosis.

The use of al is also particularly preferred. minus one of the respective compounds of pyrazoline azepan or azocansubstituted, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or treatment of disorders of food intake, preferably bulimia, anorexia, cachexia, obesity and / or diabetes mellitus type II (diabetes mellitus not insulin dependent), more preferably obesity.

Also particularly preferred is the use of the minus one of the pyrazoline compounds, as defined in the present invention, and optionally one or more excipients pharmaceutically acceptable, for the preparation of a medicine for the treatment of metabolic syndrome.

The metabolic syndrome and its definitions are described in detail by Eckel et al , The Lancet, Vol 365 (2005), 1415-1428, included herein as a reference. One of the respective definitions was established by WHO in 1998 (as described in Alberti et al ., Diabet. Med. 1998, 15, pages 539-53, the respective descriptions are incorporated by reference to this document and are part of the description). The other more widely accepted definition of metabolic syndrome was established by the Adult Treatment Panel (ATP III) of the US National Cholesterol Education Program (NCEP) in 2001, as described in JAMA 2001; 285; 2486-97, the respective descriptions are incorporated by reference to this document and are part of the description.

The metabolic syndrome is characterized by a interaction of several physiological parameters such as triglycerides, lipids, blood pressure, glucose levels and insulin levels

Even though obesity plays a role critical in the development of metabolic syndrome, many of its aspects are independent of weight, especially some lipid parameters. Especially the positive influence on independent aspects of the weight of the metabolic syndrome (see for example, Pagotto and Pasquali, The Lancet, Vol. 365 (2005), 1363, 1364, included herein as a reference) as some blood parameters, especially lipid parameters It is one of the main and surprising advantages of substituted pyrazoline compounds used according to the invention.

       \ vskip1.000000 \ baselineskip
    

Another aspect of the invention is the use of one or more pyrazoline compounds, as defined herein document, for the manufacture of a medicine for the improvement of cardiovascular and / or metabolic risk factors, such as one or more of the following factors:

Triglycerides elevated, in which elevated triglyceride levels are preferably understand that they are> 150 mg / dl,

Cholesterol low HDL, in which the low cholesterol levels of HDL it is preferably understood that they are <40 mg / dl in men and < 50 mg / dl in women,

Hypertension, in which hypertension is preferably understood to be> 130/85 mmHg,

Alteration of the fasting glucose, in which the alteration of fasting blood glucose preferably understood to be> 110 mg / dl,

Resistance to insulin,

Dyslipidemia

Another aspect of the invention is the use of one or more pyrazoline compounds, as defined herein document, for the manufacture of a drug for treatment of the independent aspects of the weight of the syndrome metabolic.

       \ vskip1.000000 \ baselineskip
    

Another aspect of the invention is a method for improve cardiovascular and / or metabolic risk factors, such as one or more of the following factors:

Triglycerides elevated, in which elevated triglyceride levels are preferably understand that they are> 150 mg / dl,

Cholesterol low HDL, in which the low cholesterol levels of HDL it is preferably understood that they are <40 mg / dl in men and < 50 mg / dl in women,

Hypertension, in which hypertension is preferably understood to be> 130/85 mmHg,

Alteration of the fasting glucose, in which the alteration of fasting blood glucose preferably understood to be> 110 mg / dl,

Resistance to insulin,

Dyslipidemia,

in a subject, preferably a human being.

       \ vskip1.000000 \ baselineskip
    

Another aspect of the invention is a method for treat independent aspects of the weight of the syndrome metabolic.

The use of al is also particularly preferred. minus one of the respective compounds of pyrazoline azepan or azocansubstituted, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicine for prophylaxis and / or cancer treatment, preferably for the prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of cancer brain, bone cancer, lip cancer, mouth cancer, cancer esophagus, stomach cancer, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, cervical cancer, cancer lung, breast cancer, skin cancer, colon cancer, cancer intestinal and prostate cancer, more preferably for prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of colon cancer, cancer Intestinal and prostate cancer.

The use of al is also particularly preferred. minus one of the respective compounds of pyrazoline azepan or azocansubstituted, optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in the form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any mixing ratio, or a corresponding N-oxide of the themselves, or a corresponding salt thereof, or a solvate corresponding thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or treatment of alcoholism and / or alcohol addiction, nicotine abuse and / or smoking, abuse of drugs and / or drug addiction and / or drug abuse and / or Drug dependence, preferably drug abuse and / or drug addiction  and / or nicotine abuse and / or smoking.

Medications / drugs, which are frequently subject to abuse include opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines.

Also preferred is the use of at least one of the respective azepan or azocansubstituted pyrazoline compounds,  optionally in the form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and / or diastereomers, in any reason of mixture, or a corresponding N-oxide thereof, or a salt corresponding thereof, or a corresponding solvate of the themselves, and optionally one or more pharmaceutically excipients acceptable, for the preparation of a prophylaxis drug and / or the treatment of one or more disorders selected from the group consisting of bone disorders, preferably osteoporosis (by example, osteoporosis associated with a genetic predisposition, deficit of sex hormones or aging), bone disease associated with cancer or bone disease of Paget; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, disorders Cognitive, cranial trauma, craniocerebral trauma, stroke, panic attacks, peripheral neuropathy, inflammation, glaucoma, migraine, Parkinson's disease, disease of Huntington, Alzheimer's disease, Raynaud's disease, tremor, compulsive disorders, senile dementia, disorders thymic, tardive dyskinesia, bipolar disorders, disorders of medication-induced movement, dystonia, shock Endotoxémico, hemorrhagic shock, hypotension, insomnia, disorders immunological, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or to influence intestinal transit.

The medicament according to the present invention can be in any form suitable for application to beings humans and / or animals, preferably humans including infants, children and adults and can be produced by usual procedures known to those skilled in the art. The medicine can be produced by usual procedures known to those skilled in the art, for example, from "Pharmaceutics: The Science of Dosage Forms" index, second edition, Aulton, M.E. (ED. Churchill Livingstone, Edinburgh (2002); "Encyclopedia of Pharmaceutical Technology", second edition, Swarbrick, J. and Boiloan J.C. (Eds.), Marcel Dekker, Inc. New York (2002); "Modern Pharmaceutics", fourth edition, Banker G.S. and Rhodes C.T. (Eds.) Marcel Dekker, Inc. New York 2002 and "The Theory and Practice of Industrial Pharmacy", Lachman L., Lieberman H. and Kanig J. (Eds.), Lea & Febiger, Philadelphia (1986). The respective descriptions are incorporated as reference to this document and are part of the description. The composition of the medication may vary depending on the route of administration.

The medicament of the present invention can, for example, administered parenterally in combination with conventional injectable liquid vehicles, such as water or suitable alcohols. Pharmaceutical excipients may be included. conventional for injection, such as stabilizing agents, solubilizing agents and buffers, in such compositions injectable These medications can be injected, for example, by intramuscularly, intraperitoneally or via intravenous

Medications according to the present invention they can also be formulated in compositions that can be administered orally, containing one or more vehicles or excipients physiologically compatible, in solid or liquid form. These compositions may contain conventional components, such as binding agents, fillers, lubricants and wetting agents acceptable. The compositions can take any form convenient, such as tablets, microgranules, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powder forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or sustained release. The forms multiparticulates, such as microgranules, can, by example, fill in a capsule, compressed into tablets or Suspend in a suitable liquid.

Formulations are known from the prior art of suitable controlled release, materials and methods for its preparation, for example, from the index of "Modified-Release Drug Delivery Technology", Rathbone, M.J. Hadgraft, J. and Roberts, M.S. (Eds.), Marcel Dekker, Inc., New York (2002); "Handbook of Pharmaceutical Controlled Release Technology ", Wise, D.L. (Ed.), Marcel Dekker, Inc. New York, (2000); "Controlled Drug Delivery", Vol, I, Basic Concepts, Bruck, S.D. (Ed.), CRD Press Inc., Boca Raton (1983) and of Takada, K. and Yoshikawa, H., "Oral Drug Delivery", Encyclopedia of Controlled Drug Delivery, Matiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 728-742; Fix, J., "Oral drug delivery, small intestine and colon", Encyclopedia of Controlled Drug Delivery, Matiowitz, E. (Ed.), John Wiley & Sons, Inc., New York (1999), Vol. 2, 698-728. The respective descriptions are incorporated as a reference to this document and are part of the description.

Medications according to the present invention they can also comprise an enteric coating, so if Solution depends on the pH value. Due to said coating, the medication can pass through the stomach without dissolving and the respective nitrosubstituted phenylpiperazine compound is released in the intestinal tract Preferably, the enteric coating is soluble at a pH value of 5 to 7.5. The materials and methods suitable for preparation are known in the art previous.

Normally, medications according to this invention may contain 1-60% by weight of one or more azepan or azocansubstituted pyrazoline compounds, such as are defined in this document and 40-99% in weight of one or more auxiliary substances (additives).

Liquid oral forms for administration they can also contain various additives such as agents sweeteners, flavorings, preservatives and emulsifiers. Too non-aqueous liquid compositions can be formulated for Oral administration containing edible oils. Such liquid compositions can be conveniently encapsulated in, by For example, gelatin capsules in a unit dose amount.

The compositions of the present invention they can also be administered topically or through a suppository.

The daily dosage for humans and Animals may vary depending on factors that are based on the respective species or other factors, such as age, sex, weight or degree of illness, etc. Dosage daily for humans can preferably be in the range from 1 to 2000, preferably 1 to 1500, more preferably from 1 to 1000, even more preferably from 1 to 150 milligrams of active substance to be administered during one or Several intakes per day.

The present invention is illustrated below. With the help of examples. These illustrations are provided by way of example only and do not limit the general spirit of the present invention

       \ vskip1.000000 \ baselineskip
    

Examples

The following compounds were prepared according to the general procedures described above. The experts in the matter they are familiar with the starting materials that they are necessary to obtain said compounds.

       \ vskip1.000000 \ baselineskip
    

a) Preparation of the compound of general acid formula 4- (phenyl 4-substituted) -2-oxo-3-butenoic

       \ vskip1.000000 \ baselineskip
    

29

(where W has the meaning facilitated previously).

       \ vskip1.000000 \ baselineskip
    

In a three-mouth flask they dissolved para-substituted benzaldehyde (95 mmol) and ethyl pyruvate (86 mmol) in 150 ml of absolute ethanol. The solution was cooled in ice to 0 ° C and an aqueous solution of NaOH (3.8 g in 45 mL of water), keeping the temperature lower or equal to 10 ° C, whereby a color precipitate formed yellow orange. The reaction mixture was stirred for 1 hour. at 0 ° C and additionally for 1.5 hours at room temperature (approximately at 25 ° C). Then, the reaction mixture was cooled. to about 5 ° C and insoluble sodium salt was isolated from 4- (phenyl acid 4-substituted) -2-oxo-3-butenoic by filtration

The filtrate was left in the refrigerator during night, whereby more precipitate formed, which separated by filtration, combined with the first fraction of the salt and washed with diethyl ether. Sodium salt of 4- (phenyl acid 4-substituted) -2-oxo-3-butenoic It was then treated with a 2N HCl solution, stirred for a few minutes and 4- (phenyl acid filtered off 4-substituted) -2-oxo-3-butenoic solid and dried to give the desired product (range of yield: 20-70%).

       \ vskip1.000000 \ baselineskip
    

Acid 4- (4-chlorophenyl) -2-oxo-3-butenoic

IR (KBr, cm -1): 3500-2500, 1719.3, 1686.5, 1603.4, 1587.8, 1081.9.

1 H-NMR (400 MHz, CDCl 3, δ): 7.4 (d, J = 8, 4 Hz, 2H), 7.5 (d, J = 16, 1 Hz, 1H), 7.6 (d, J = 8, 4 Hz, 2H), 8.1 (d, J = 16, 1 Hz, 1H).

       \ vskip1.000000 \ baselineskip
    

Acid 4- (4-bromophenyl) -2-oxo-3-butenoic

1 H-NMR (400 MHz, CDCl 3, δ): 7.55 (2H, m, ArH), 7.61 (3H, m, Ar H), 8.09 (1H, d, J = 16, 4 Hz).

13 C NMR (400 MHz, CDCl 3, δ): 118.1 (CH), 127.2 (C), 130.7 (CH), 132.7 (CH), 149.7 (C + CH), 160.0 (CO), 182.2 (CO).

       \ vskip1.000000 \ baselineskip
    

Acid 4- (4-fluorophenyl) -2-oxo-3-butenoic

1 H-NMR (400 MHz, CDCl 3, δ): 7.15 (2H, apt, J 8.4 Hz, ArH), 7.53 (1H, d, J 16.0 Hz, CH), 8.11 (1H, d, J = 16.0 Hz).

13 C NMR (100 MHz, CDCl 3, δ): 116.5 (CH, d, JF 24 Hz), 117.4 (CH, d, JF 8.7 Hz), 130.1 (C, d, J F 2.4 Hz), 131.7 (CH, d, J F 9.1 Hz), 149.9 (CH), 162.0 (C, d, JF 320 Hz), 166.7 (CO), 182.4 (CO).

       \ vskip1.000000 \ baselineskip
    

Acid 4- (4-methoxyphenyl) -2-oxo-3-butenoic

1 H-NMR (400 MHz, CDCl 3, δ): 3.88 (3H, s, OCH 3), 6.95 (2H, d, J 6.8 Hz), 7.45 (2H, d, J 15.6 H), 7.65 (2H, d, J 6.8 Hz), 8.09 (2H, d, J 15.6 Hz)

       \ vskip1.000000 \ baselineskip
    

b) Preparation of the compound of general acid formula 5- (phenyl 4-substituted) -1- (chlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

30

(where W has the meaning given above and X = Cl, H).

4- (Phenyl acid) was mixed 4-substituted) -2-oxo-3-butenoic obtained according to step a) (60 mmol), hydrochloride 2,4-dichlorophenylhydrazine or 2-chlorophenylhydrazine (60 mmol) and acetic acid glacial (200 mL) under a nitrogen atmosphere and heated to reflux for 4 hours, cooled to room temperature (approximately 25 ° C) and added to ice water, by which obtained a sticky dough that was extracted with methylene The combined methylene chloride fractions are washed with water, dried with sodium sulfate, filtered and evaporated to dryness to give a pale yellow solid or white (yield range 10-90%). Both enantiomers of this acid can be separated by chiral HPLC or by crystallization of the diastereoisomeric salts formed with chiral amines (ee ≥ 99% is obtained).

       \ vskip1.000000 \ baselineskip
    

Acid 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (KBr, cm -1): 3200-2200, 1668.4, 1458, 1251.4, 1104.8.

1 H-NMR (400 MHz, CDCl 3, δ): 3.3 (dd, 1H), 3.7 (dd, 1H), 5.9 (dd, 1H), 7.09-7.25 (m, 7H).

       \ vskip1.000000 \ baselineskip
    

Acid 5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (KBr, cm -1): 3200-2200, 1685, 1571, 1549, 1480, 1112

1 H-NMR (400 MHz, CDCl 3, δ): 3.27 (1H, dd, J 18.0, 6.4 Hz, ArH), 3.71 (1H, dd, J 18, 12.8 Hz, Ar H), 5.88 (1H, dd, J 12.8, 6.4 Hz, CH), 7.02 (2H, d, J 7.6 Hz, Ar H), 7.08 (1H, m, ArH), 7.19 (1H, d, J 8.4 Hz, ArH), 7.26 (1H, m ArH), 7.37 (2H, d, 7.6 Hz, ArH).

13 C NMR (100 MHz, CDCl 3, δ): 40.4 (CH2), 67.4 (CH), 122.7 (C), 126.0 (CH), 126.5 (C), 127.6 (CH), 128.3 (CH), 130.2 (CH), 131.2 (C), 132.2 (CH), 138.4 (C), 138.5 (C), 140.2, (C), 165.7 (C).

       \ vskip1.000000 \ baselineskip
    

Acid 5- (4-fluorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (KBr, cm -1): 3200-2200, 1687.5, 1478, 1230, 1107

1 H-NMR (400 MHz, CDCl 3, δ): 3.30 (1H, dd, J 18.0, 6.4 Hz, ArH), 3.72 (1H, dd, J 18, 12.8 Hz, Ar H), 5.93 (1H, dd, J 12.8, 6.4 Hz, CH), 6.92 (2H, t, J 8.4 Hz, ArH), 7.09-7.12 (3H, m, ArH), 7.22 (1H, bs, ArH), 7.26 (1H, m ArH).

13 C NMR (100 MHz, CDCl 3, δ): 40.7 (CH 2), 67.8 (CH), 115.9 (CH, d, J F 21 Hz), 126.1 (CH), 126.5 (C), 127.6 (CH), 128.3 (CH, d, JF 8.2 Hz), 130.1 (CH), 131.2 (C), 135.1 (C, d, JF3 Hz), 138.6 (C), 140.1 (C), 160.6, (C, d, JF 240 Hz), 166.3 (C).

       \ vskip1.000000 \ baselineskip
    

Acid 5- (4-methoxyphenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (NaCl film, cm -1) nu 1938, 2833, 1663, 1476

IR (KBr, cm -1): \ nu 3200-2200, 1685, 1513, 1478, 1248, 1105

1 H-NMR (400 MHz, CDCl3, δ): 1.45 (2H, m, CH2), 1.75 (4H, m), 2.84 (4H, m), 3.45 (1H, dd, J 4.8, 18 Hz), 3.61 (1H, dd J 11.2, 19.6 Hz), 5.93 (1H, dd, J 4.8 11.2 Hz), 6.57 (2H, ap, s), 7.13 (2H, m), 7.32 (1H, m), 7.40 (1H, m).

13 C NMR (100 MHz, CDCl 3, δ): 23.4 (CH2), 25.3 (CH2), 40.5 (CH2), 57.3 (CH2), 63.7 (CH), 125.7 (CH), 125.8 (CH), 126.1 (CH), 127.1 (C), 127.8 (CH), 130.1 (CH), 131.1 (C), 139.6, (C), 139.9 (C), 146.1 (C), 158.9 (CO).

       \ vskip1.000000 \ baselineskip
    

(c) 5- (Phenyl acid chloride) 4-substituted) -1- (chloro-phenyl) -4,5-dihydro-pyrazol-3-carboxylic

31

(where W and X have the meaning facilitated previously).

The acid 5- (phenyl) was dissolved 4-substituted) -1- (2,4-dichlorophenyl) or (2-Chlorophenyl) -4,5-dihydropyrazol-3-carboxylic  (15 mmol) obtained according to step (b) in 120 mL of toluene anhydrous and thionyl chloride (18 mmol). The mixture was heated up to 80 ° C for 2.5 hours. The solvent is removed under pressure reduced and the resulting crude residue is used without purification additional.

       \ vskip1.000000 \ baselineskip
    

Acid chloride 5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (KBr, cm -1): 1732, 1700, 1533, 1478, 1212, 826.

       \ vskip1.000000 \ baselineskip
    

Acid chloride 5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (KBr, cm -1): 1737, 1534, 1477, 1212, 1127

       \ vskip1.000000 \ baselineskip
    

Acid chloride 5- (4-fluorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (KBr, cm -1): 1733, 1548, 1511, 1478, 1212, 832.

       \ vskip1.000000 \ baselineskip
    

Acid chloride 5- (4-methoxyphenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic

IR (KBr, cm -1): 1735, 1513, 1477, 1249, 1129

       \ vskip1.000000 \ baselineskip
    

d) N- (azepan-1-yl) -5- (phenyl 4-substituted) -1- (2,4-dichlorophenyl) (or 2-chlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide  or azepan-1-il-5- (phenyl 4-substituted) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-yl) methanone

32

(where W, R 5, R 6 and R 7 and X have the meaning given previously).

Under nitrogen atmosphere, they dissolved azepan or azepan-1-amine (5.6 mmol) and triethylamine (4 mL) in methylene chloride (25 mL). Mix resulting was cooled with ice to 0 ° C and a drop was added dropwise.  5- (Phenyl acid chloride solution 4-substituted) -1- (2,4-dichlorophenyl) -4,5-dihydro-pyrazol-3-carboxylic  (4.6 mmol) obtained in step (c) in methylene chloride (15 mL) The resulting reaction mixture was stirred at temperature. ambient (approximately 25 ° C) overnight. Then the mixture reaction was washed with water, followed by an aqueous solution saturated sodium bicarbonate, then again with water, it dried over sodium sulfate, filtered and evaporated to dryness on a rotary evaporator. The resulting crude solid crystallized from ethanol. The crystallized solid was filtered off and the mother waters were concentrated to give a second fraction of crystallized product The two fractions were combined to give the desired product (performance range: 60-80%) Alternatively, the compound can be purify by crystallization of its hydrochloride form, prepared with a solution of 2N HCl in ether or 2.8 N HCl in ethanol.

If the starting material in step c) is a chiral acid

       \ vskip1.000000 \ baselineskip
    

Example one

N- (azepan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide (one)

       \ vskip1.000000 \ baselineskip
    

33

       \ vskip1.000000 \ baselineskip
    

1 H-NMR (400 MHz, CHLOROFORM-d) δ ppm 1.63 (m, 4 H) 1.80 (m, 4 H) 3.22 (dd, J = 18.31, 6.15 Hz, 1 H) 3.30 (m, 4 H) 3.61 (dd, J = 18.31, 12.30 Hz, 1 H) 5.70 (dd, J = 12.30, 6.15 Hz, 1 H) 6.99 (m, 3H) 7.10 (m, 3 H) 7.19 (m, 1 H).

       \ vskip1.000000 \ baselineskip
    

Example 4

N- (azepan-1-yl) -5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide

       \ vskip1.000000 \ baselineskip
    

3. 4

       \ vskip1.000000 \ baselineskip
    

1 H-NMR (300 MHz, CHLOROFORM-d) δ ppm 1.75 (br. S., 4 H) 2.00 (br. s., 4 H) 3.26 (dd, J = 18.16, 6.15 Hz, 1 H) 3.71 (dd, J = 18.16, 12.45 Hz, 1 H) 3.65 (br. S., 4 H) 5.82 (dd, J = 12.45, 6.15 Hz, 1 H) 6.97 (d, J = 8.35 Hz, 2 H) 7.10 (d, J = 2.20 Hz, 1 H) 7.16 - 7.22 (m, 1 H) 7.24 (d, J = 2.20 Hz, 1 H) 7.35 (d, J = 8.50 Hz, 2 H).

       \ vskip1.000000 \ baselineskip
    

Example 7

N- (azepan-1-yl) -5- (4-fluorophenyl) 1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide

       \ vskip1.000000 \ baselineskip
    

35

       \ vskip1.000000 \ baselineskip
    

1 H-NMR (300 MHz, DMSO-d_6) δ ppm 1.75 (br. S., 4 H) 2.00 (br. s., 4 H) 3.28 (dd, J = 18.16, 6.08 Hz, 1 H) 3.68 (dd, J = 18.16, 12.38 Hz, 1 H) 3.68 (br. S., 4 H) 5.84 (dd, J = 12.38, 6.08 Hz, 1 H) 6.90 (t, J = 8.57 Hz, 2 H) 7.08 (m, 3 H) 7.14 - 7.19 (m, 1 H) 7.24 (d, J = 2.20 Hz, 1 H).

       \ newpage
    

Example eleven

Hydrochloride N- (azepan-1-yl) -5- (4-methoxyphenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide

       \ vskip1.000000 \ baselineskip
    

36

       \ vskip1.000000 \ baselineskip
    

1 H-NMR (300 MHz, METHANOL-d4) δ ppm 1.77 (br. S., 4 H) 1.98 (br. S., 4 H) 3.27 (dd, J = 6.15 Hz, 1 H) 3.63 (m, 5 H) 3.70 (s, 3 H) 5.90 (dd, J = 12.45, 6.15 Hz, 1 H) 6.76 (d, J = 8.64 Hz, 2 H) 7.16 (dd, J = 8.64, 2.20 Hz, 1 H) 7.10 (d, J = 8.64 Hz, 2 H) 7.33 (m, 2 H).

       \ vskip1.000000 \ baselineskip
    

Example 2. 3

N- (azocan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide

       \ vskip1.000000 \ baselineskip
    

37

       \ vskip1.000000 \ baselineskip
    

1 H-NMR (300 MHz, METHANOL-d4) δ ppm 1.76 (br. S., 6 H) 2.01 (br. S., 4 H) 3.26 (dd, J = 18.02, 6.52 Hz, 1 H) 3.65 (m, 4 H) 3.76 (dd, J = 18.02, 12.52 Hz, 1 H) 5.96 (dd, J = 12.52, 6.52 Hz, 1 H) 7.16 - 7.28 (m, 5 H) 7.40 (d, J = 8.64 Hz, 1 H) 7.37 (d, J = 2.34 Hz, 1 H).

       \ vskip1.000000 \ baselineskip
    

Example 2. 3

N- (azocan-1-yl) -1- (2-chlorophenyl) -5- (4-methoxyphenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide

       \ vskip1.000000 \ baselineskip
    

38

       \ vskip1.000000 \ baselineskip
    

1 H-NMR (300 MHz, CHLOROFORM-d) δ ppm 1.53 - 1.62 (m, 2 H) 1.68 (br. s., 8 H) 3.10 (m, 4 H) 3.34 (dd, J = 18.31, 6.01 Hz, 1 H) 3.64 (dd, J = 18.31, 12.01 Hz, 1 H) 3.72 (s, 3 H) 5.68 (dd, J = 12.01, 6.01 Hz, 1 H) 6.70 (d, J = 8.64 Hz, 2 H) 7.03 (m, 3 H) 7.08 - 7.13 (m, 1 H) 7.23 (d, J = 2.34 Hz, 1 H) 7.93 (br.s., 1 H).

39

40

41

42

43

44

Pharmacological data Pharmacological methods I. In vitro determination of affinity for CB1 / CB2 receptors

In-vitro determination of the affinity of the substituted pyrazoline compounds of the invention by the CB1 / CB2 receptors is carried out as described in the publication of Ruth A. Ross, Heather C. Brockie et al ., "Agonist-inverse agonist characterization at CB_ {1} and CB_ {2} cannabinoid receptors of L-759633, L759656 and AM630", British Journal of Pharmacology, 126, 665-672, (1999), in which Transfected human CB 1 and CB 2 receptors from Receptor Biology, Inc. are used. The radioligand used for both receptors is [3 H] -CP55940. The respective parts are incorporated by reference to this document and are part of this description.

       \ vskip1.000000 \ baselineskip
    

Results

The affinity of pyrazoline compounds substituted of the invention by the CB1 / CB2 receptors are determined as described above. Some of the EC50 values obtained are provided in Table 3.

As can be seen from the given values in table 3, the pyrazoline compounds of the invention are particularly suitable for regulating the CB1 receptor.

       \ vskip1.000000 \ baselineskip
    

II. In vivo bioassay system to determine cannabinoid Z activity Mouse tetrad model

It is known that substances with affinity for cannabinoid receptors produce a wide range of effects Pharmacological It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in Mice produces analgesia, hypothermia, sedation and catalepsy. Individually, none of these effects can be considered as proof that a tested substance has an affinity for cannabinoid receptors, since all these effects are common for various kinds of active agents in the nervous system central. However, the substances that show all these effects, that is, the substances that are active in this model called tetrad, they are considered to have affinity for cannabinoid receptors It has also been shown that cannabinoid receptor antagonists are extremely effective in blocking the effects of a cannabinoid agonist in the mouse tetrad model.

The tetrad model is described, for example, in the publication of AC Howlett et al , International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors, Pharmacol Rev 54, 161-202, 2002 and David R. Compton et al ., " In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A): Inhibition of Tetrahydrocannbinol-induced Responses and Apparent Agonist Activity", J. Pharmacol. Exp. Ther. 277, 2, 586-594, 1996. The corresponding parts of the description are incorporated by reference to this document.

       \ vskip1.000000 \ baselineskip
    

Material and methods

In all the following experiments they are used NMRI male mice weighing 20-30 g (Harlan, Barcelona, Spain).

Before the tests in the procedures behavioral behaviors then the mice acclimatize to the experimental environment. Control values prior to treatment were determined to measure analgesia using hot plate latency (in seconds), rectal temperature, sedation and catalepsy.

In order to determine agonist activity of the substance to be tested, mice are injected via intravenous the substance to be tested or the vehicle alone. fifteen minutes after injection, analgesia latency is measured in hot plate. 20 minutes after the injection the rectal temperature, sedation and catalepsy.

In order to determine the activity antagonist, the identical procedure is used as for determination of agonist effects, but with the difference of that the substance to be evaluated to determine its activity antagonist is injected 5 minutes before intravenous injection of 1.25 mg / kg of Win-55,212, a known agonist of the cannabinoid receptor.

       \ vskip1.000000 \ baselineskip
    

Hot plate analgesia

Hot plate analgesia is determined according to the method described in Woolfe D. et al . "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther. 80, 300-307, 1944. The respective description is incorporated as a reference to this document and is part of this description.

The mice are placed on a hot plate (Harvard analgesimeter) at 55 ± 0.5 ° C until they show a painful sensation, licking its legs or jumping, and registers the time for these sensations to occur. This reading is consider as the baseline value (B). The maximum time limit that is allows mice to remain on the hot plate in absence of any painful response is 40 seconds with the In order to avoid skin lesions. This period is called time. limit (PC).

Fifteen minutes after the administration of the substance to be tested, the mice are placed again on the hot plate and the procedure is repeated above described This period is called post-treatment reading. (PT).

       \ newpage
    

The degree of analgesia is calculated from the formula:

MPE% of analgesia = (PT-B) / (PC-B) x 100

MPE = maximum possible effect.

       \ vskip1.000000 \ baselineskip
    

Determination of sedation and ataxia

Sedation and ataxia are determined according to the method described in Desmet LKC et al . "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim. -Forsch. (Frug Res) 25, 9, 1975. The respective description is incorporated by reference to this document and forms part of this description.

The scoring system chosen is

0:

without ataxia;

one:

doubtful;

2:

tranquility and silence obvious;

3:

pronounced ataxia;

before, in addition to after treatment.

       \ vskip1.000000 \ baselineskip
    

The percentage of sedation is determined according to the formula:

% sedation  = arithmetic mean / 3 X 100

Hypothermia

Hypothermia is determined according to the method described in David R. Compton et al . " In-vivo Characterization of a Specific Cannabinoid Antagonist Receptor (SR141716A) Inhibition of Tetrahydrocannbinol-induced Responses and Apparent Agonist Activity", J. Pharmacol Exp Ther. 277, 2, 586-594, 1996. The respective description is incorporated by reference to this document and forms part of this description.

Rectal temperatures are determined initials with a thermometer (Yello Springs Instruments Co., Panlabs)  and a thermistor probe inserted 25 mm before the administration of the substance to be tested. Temperature rectal is measured again 20 minutes after administration of the substances to be tested. The temperature difference is calculate for each animal, so that the differences ≥ -2 ° C is They consider that they represent activity.

       \ vskip1.000000 \ baselineskip
    

Catalepsy

Catalepsy is determined according to the method described in Alpermann HG et al . "Pharmacological effects of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282. 1992. The respective description is incorporated by reference to this document and forms part of this description.

The cataleptic effect of the substance that is going to be tested is evaluated according to the duration of the catalepsy, putting the animals head down with their legs on top of the wood block.

       \ vskip1.000000 \ baselineskip
    

The scoring system chosen is:

Catalepsy during:

more than 60 seconds = 6; 50 -60 seconds = 5, 40-50 seconds = 4, 30-40 seconds = 3, 20-30 seconds = 2, 5-10 seconds = 1, and less than 5 seconds = 0.

       \ vskip1.000000 \ baselineskip
    

The percentage of catalepsy is determined according to the following formula:

% from catalepsy = arithmetic mean / 6 X 100

Antagonistic test Materials and methods Membrane Preparation

Chinese hamster ovary cells were cultured (CHO) that stably express the cannabinoid receptor recombinant human 1 in a mixture of Ham F12 nutrients supplemented with 10% fetal bovine serum inactivated with the heat, 2 mM L-glutamine, 50 U / ml penicillin, 50 U / ml streptomycin and 0.5 mg / ml geneticin. With the purpose of to obtain cells, the culture flasks were washed twice with phosphate buffered saline and scratched. TO The cells were then collected by centrifugation (200  x g, 10 minutes) and stored dry at -80 ° C. The cells are homogenized in ice cold 20 mM HEPES, 10 mM EDTA (pH 7.5) and centrifuged at 40,000 x g for 15 minutes at 4 ° C. He pellet was resuspended in 20 mM HEPES, 0.1 mM EDTA (pH 7.5) and centrifuged for 15 minutes at 4 ° C. The final pellet was resuspended in 20 mM HEPES, 0.1 mM EDTA (pH 7.5) and divided into parts aliquots and stored at -80 ° C until use.

       \ vskip1.000000 \ baselineskip
    

[35 S] GTPγS binding assay

The reaction was performed in 96-well plates. The membranes were incubated (15 µg / well) for 60 minutes at 30 ° C in buffer (50 mM HEPES, 100 mM KCl, 5 mM MgCl 2, 1 mM EDTA, 0.1% w / v bovine serum albumin, 5 µM GDP, saponin (10 mug / ml), [35 S] GTP γ 0.5 nM, pH 7.4) with a compound at a final concentration of 1 µM in the absence or presence of an agonist dose-response curve WIN 55,212-2 between 3 nM and 3 µM. Incubation It was terminated by rapid filtration through FB fiberglass  Millipore Multiscreen and rinsed twice with assay buffer ice cold The filtering plates were dried and added. 30 µl of scintillation liquid. The radioactivity was determined using Wallac Microbeta Trilux. Each experiment was performed at less in duplicate. A systematically performed WIN dose response 55,212-2.

       \ vskip1.000000 \ baselineskip
    

Calculations

The average union of [35 S] GTP? Baseline was subtracted from all data of Union. In order to compare the results of antagonism of one screening group with respect to another, the difference between the maximum agonist effect of Win 55,212-2 alone and the maximum antagonism effect due to WIN 55,212-2 more Rimonabant (1 µM) was defined as 100%.

       \ vskip1.000000 \ baselineskip
    

Results

The determination of cannabinoid activity in vivo was determined as described above. The antagonistic effect (against Win 55212-2) was determined for some of the compounds as indicated in the following Table 3.

The test results of some of the previous examples for binding and antagonism are shown together in the following table 3:

TABLE 3

Four. Five

III. In vivo tests to determine activity against obesity a) Acute treatment

Normally treated rats were habituated to a reverse cycle 12/12 h, and the candidate compound, as well as the saline solution, were administered orally acutely. After after administration, the intake of accumulated food (g). After this, the difference in body weight between control animals and animals treated with the compound.

Figure 1 shows the results for 10 mg / kg of the compound according to example 2. The number of rats used was of 11 for saline and 12 for the compound.

       \ vskip1.000000 \ baselineskip
    

b) Long-term treatment

In vivo tests to determine the activity against obesity of the pyrazoline compounds of the invention are carried out as described in the publication of G. Colombo et al ., "Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR 141716 "; Life Sciences, 63 (8), 113-117, (1998). The respective part of the description is incorporated as a reference to this document and is part of this description.

       \ vskip1.000000 \ baselineskip
    

IV. In vivo tests to determine antidepressant activity

In vivo tests to determine the antidepressant activity of the pyrazoline compounds of the invention in the forced swimming test are carried out as described in the publication of ET Tzavara et al ., "The CB1 receptor antagonist SR141716A selectively increases monoaminargic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions "; Br. J. Pharmacol. 2003, 138 (4): 544: 53. The respective part of the description is incorporated as a reference to this document and is part of this description.

Claims (29)

1. Pyrazoline compounds azepan or azocansubstituted of general formula I

         \ vskip1.000000 \ baselineskip
      

46

         \ vskip1.000000 \ baselineskip
      

in the that X and Y independently represent phenyl, thienyl, naphthyl or pyridyl, whose groups may be substituted with 1, 2 or 3 substituents W, which may be the same or different, selected from the group

I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, CHF2, CH 2 F, OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -alkyl C 1-20;

         \ vskip1.000000 \ baselineskip
      

- R 8 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 9 represents

         \ vskip1.000000 \ baselineskip
      

47

         \ vskip1.000000 \ baselineskip
      

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

or

         \ newpage
      

- R 8 and R 9 together with the atom of connecting nitrogen represent

         \ vskip1.000000 \ baselineskip
      

48

         \ vskip1.000000 \ baselineskip
      

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing; in the form shown or in the form of the acid or the base or in the form of a salt, especially a physiologically salt acceptable, or in the form of a solvate, especially a hydrate or in corresponding N-oxide form thereof.

         \ vskip1.000000 \ baselineskip
      

2. Pyrazoline compounds azepan or azocansubstituted of general formulas Ia or Ib according to the claim 1,

         \ vskip1.000000 \ baselineskip
      

49

         \ vskip1.000000 \ baselineskip
      

in the that X and Y independently represent phenyl, thienyl, naphthyl or pyridyl, whose groups may be substituted with 1, 2 or 3 substituents W, which may be the same or different, selected from the group:

I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, CHF2, CH 2 F, OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -alkyl C 1-20;

         \ newpage
      

- R 8 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 9 represents fifty

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

or - R 8 and R 9 together with the atom of connecting nitrogen represent 51

selecting R 5, R 6 and R 7, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and n being 1 or 2;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate, or in the form of a corresponding N-oxide of the same.

         \ vskip1.000000 \ baselineskip
      

3. Pyrazoline compounds azepan or azocansubstituted of general formula II according to claim one, 52 in the that R 11, R 12, R 13 and R 14, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, CHF2, CH 2 F, OCHF 2, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

         \ vskip1.000000 \ baselineskip
      

- R 18 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 19 represents

         \ vskip1.000000 \ baselineskip
      

53

         \ vskip1.000000 \ baselineskip
      

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2;

or - R 18 and R 19 together with the atom of connecting nitrogen represent

         \ vskip1.000000 \ baselineskip
      

54

         \ vskip1.000000 \ baselineskip
      

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2;

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing; in the form shown or in the form of the acid or the base or in the form of a salt, especially a physiologically salt acceptable, or in the form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

         \ newpage
      

4. Pyrazoline compounds azepan or azocansubstituted of general formulas IIa or IIb according to the claim 3,

         \ vskip1.000000 \ baselineskip
      

55

         \ vskip1.000000 \ baselineskip
      

in the that R 11, R 12, R 13 and R 14, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, CHF2, CH2F, OCHF2, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, indicating P a prodrug group that consists of aryl, C 8-20 alkyl, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

         \ vskip1.000000 \ baselineskip
      

- R 18 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 19 represents

         \ vskip1.000000 \ baselineskip
      

56

         \ vskip1.000000 \ baselineskip
      

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2;

or

         \ newpage
      

- R 18 and R 19 together with the atom of connecting nitrogen represent

         \ vskip1.000000 \ baselineskip
      

57

         \ vskip1.000000 \ baselineskip
      

selecting R 15, R 16 and R 17, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; and m being 1 or 2;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

         \ vskip1.000000 \ baselineskip
      

5. Azepan or azocansubstituted pyrazoline compounds according to any of claims 3 or 4, characterized in that R 11, R 12, R 13 and R 14, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

         \ vskip1.000000 \ baselineskip
      

preferably R 11, R 12, R 13 and R 14, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3.

         \ vskip1.000000 \ baselineskip
      

6. Azepan or azocansubstituted pyrazoline compounds according to any of claims 3 to 5, characterized in that R 18 represents H.

         \ vskip1.000000 \ baselineskip
      

7. Azepan or azocansubstituted pyrazoline compounds according to any of claims 3 to 6, characterized in that R 15, R 16, and R 17 are selected, independently of each other, from H, F, Cl, Br, I, OH, CH 3, C 2 H 5, OCH 3, OCF 3 or CF 3.

         \ newpage
      

8. Pyrazoline compounds azepan or azocansubstituted of general formula III according to the claims 1 or 3,

         \ vskip1.000000 \ baselineskip
      

58

         \ vskip1.000000 \ baselineskip
      

in the that R 21, R 22, R 23 and R 24, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl;

         \ vskip1.000000 \ baselineskip
      

- R 28 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 29 represents

         \ vskip1.000000 \ baselineskip
      

59

         \ vskip1.000000 \ baselineskip
      

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

or

         \ newpage
      

- R 28 and R 29 together with the atom of connecting nitrogen represent

         \ vskip1.000000 \ baselineskip
      

60

         \ vskip1.000000 \ baselineskip
      

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing; in the form shown or in the form of the acid or the base or in the form of a salt, especially a physiologically salt acceptable, or in the form of a solvate, especially a hydrate or in form of a corresponding N-oxide thereof.

         \ vskip1.000000 \ baselineskip
      

9. Pyrazoline compounds azepan or azocansubstituted general formulas IIIa and IIIb according to the claim 8, 61 in the that R 21, R 22, R 23 and R 24, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl; - R 28 represents a hydrogen atom or a C 1-3 branched or linear alkyl group, while R 29 represents 62

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

or - R 28 and R 29 together with the atom of connecting nitrogen represent 63

selecting R 25, R 26 and R 27, independently of each other, of H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; p being 1 or 2;

optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

         \ vskip1.000000 \ baselineskip
      

10. Azepan or azocansubstituted pyrazoline compounds according to any of claims 8 or 9, characterized in that R 21 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while R 22, R 23 and R 24, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

         \ vskip1.000000 \ baselineskip
      

preferably R 21 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while R 22, R 23 and R 24, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

         \ vskip1.000000 \ baselineskip
      

more preferably R 21 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while R 22, R 23 and R 24, independently of each other, they represent OH, OCH 3, F, Cl, Br, I, or OCF_ {3}.

         \ vskip1.000000 \ baselineskip
      

11. Azepan or azocansubstituted pyrazoline compounds according to any of claims 8 or 9, characterized in that R 21, R 22, R 23 and R 24, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

         \ vskip1.000000 \ baselineskip
      

preferably R 21, R 22, R 23 and R 24, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

         \ vskip1.000000 \ baselineskip
      

more preferably R 21 represents H, while R 22, R 23 and R 24, independently of each other, represent OH, OCH_ {3}, F, Cl, Br, I, or OCF_ {3}.

         \ vskip1.000000 \ baselineskip
      

12. Azepan or azocansubstituted pyrazoline compounds according to any of claims 8 to 11, characterized in that R 28 represents H.

         \ vskip1.000000 \ baselineskip
      

13. Azepan or azocansubstituted pyrazoline compounds according to any of claims 8 to 12, characterized in that R 25, R 26 and R 27, independently of each other, they are selected from H, F, Cl, Br, I, OH, CH 3, C 2 H 5, OCH 3, OCF 3, or CF 3.

         \ vskip1.000000 \ baselineskip
      

14. Azepansubstituted pyrazoline compounds of general formulas IV, IVa and IVb according to claim 8,

         \ vskip1.000000 \ baselineskip
      

64 in the that R 31, R 32, R 33 and R 34, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl; R 35, R 36 and R 37, independently of each other, they are selected from H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; R 38 represents a hydrogen atom or a C 1-3 linear or branched group; optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

         \ vskip1.000000 \ baselineskip
      

15. Azepansubstituted pyrazoline compounds of general formulas IVc, IVd and IVe according to claim 8, 65 in the that R 31, R 32, R 33 and R 34, independently of each other, they represent H; I rent C 1-3 branched or linear or alkoxy C 1-3 branched or linear, phenyl, hydroxyl, chlorine, bromine, fluoro, iodine, SH, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl; O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl; R 35, R 36 and R 37, independently of each other, they are selected from H, F, Cl, Br, I, OH, SH, C 1-4 alkyl, alkoxy C 1-4, CF 3, CHF 2, CH 2 F, OCF 3, a keto group, NO 2 or NH 2; optionally in the form shown or in form of the acid or base or in the form of a salt, especially a salt physiologically acceptable, or in the form of a solvate, especially a hydrate or in the form of a corresponding N-oxide of the same.

         \ vskip1.000000 \ baselineskip
      

16. Azepansubstituted pyrazoline compounds according to any of claims 14 or 15, characterized in that R 31 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while R 32, R 33 and R 34, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

         \ vskip1.000000 \ baselineskip
      

preferably R 31 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while R 32, R 33 and R 34, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

         \ vskip1.000000 \ baselineskip
      

more preferably R 31 represents O-P, P indicating a prodrug group consisting of aryl, alkyl C 8-20, heteroaryl, C (O) -aryl, C (O) -heteroaryl, C (O) -C 1-20 alkyl, while R 32, R 33 and R 34, independently of each other, they represent OH, OCH 3, F, Cl, Br, I, or OCF_ {3}.

         \ vskip1.000000 \ baselineskip
      

17. Azepansubstituted pyrazoline compounds according to any of claims 14 or 15, characterized in that R 31, R 32, R 33 and R 34, independently of each other, they represent H, CH 3, C 2 H 5, C 3 H 7, OCH 3, OC 2 H 5, OH, SH, F, Cl, Br, I, CF 3, CHF 2, CH 2 F, OCF 3, OCHF2;

         \ vskip1.000000 \ baselineskip
      

preferably R 31, R 32, R 33 and R 34, independently of each other, they represent H, OH, OCH 3, F, Cl, Br, I, CF 3, CHF 2 or OCF 3;

         \ vskip1.000000 \ baselineskip
      

more preferably R 31 represents H, while R 32, R 33 and R 34, independently of each other, represent OH, OCH_ {3}, F, Cl, Br, I, or OCF_ {3}.

         \ vskip1.000000 \ baselineskip
      

18. Azepansubstituted pyrazoline compounds according to any of claims 14 to 17, characterized in that R 38 represents H.

         \ vskip1.000000 \ baselineskip
      

19. Azepansubstituted pyrazoline compounds according to any of claims 14 to 18, characterized in that R 35, R 36 and R 37, independently of each other, they are selected from H, F, Cl, Br, I, OH, CH 3, C 2 H 5, OCH 3, OCF 3, or CF 3.

         \ vskip1.000000 \ baselineskip
      

20. Compound according to claim 14 selected from the group consisting of: ? N- (azepan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide, ? (R) -N- (azepan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide, ? (S) -N- (azepan-1-yl) -5- (4-chlorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide, ? N- (azepan-1-yl) -5- (4-bromophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide, ? N- (azepan-1-yl) -5- (4-fluorophenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide, ? N- (azepan-1-yl) -5- (4-methoxyphenyl) -1- (2,4-dichlorophenyl) -4,5-dihydro-1H-pyrazol-3-carboxamide, optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing; optionally in the form of an N-oxide corresponding, a corresponding salt or a solvate correspondent.

         \ vskip1.000000 \ baselineskip
      

21. Compound according to claim 15 selected from the group consisting of: ? (azepan-1-yl) -1- (2,4-dichlorophenyl) -5- (4-chlorophenyl) -4,5-dihydro-1H-pyrazol-3-yl) methanone optionally in the form of your racemate, pure stereoisomers, especially enantiomers or diastereomers, or in the form of stereoisomer mixtures, especially enantiomers or diastereomers, in any reason of mixing; optionally in the form of an N-oxide corresponding, a corresponding salt or a solvate correspondent.

         \ vskip1.000000 \ baselineskip
      

22. Process for the manufacture of substituted pyrazoline compounds of general formula I according to one or more of claims 1 to 2, characterized in that at least one benzaldehyde compound of general formula V 66

         \ vskip1.000000 \ baselineskip
      

in which X has the meaning according to one or more of claims 1 or 2, it is reacted with a pyruvate compound of the general formula (SAW) 67

         \ vskip1.000000 \ baselineskip
      

in which G represents an OR group R being a branched C 1-6 alkyl radical or unbranched or G represents a group O - K with K being a cation, to give a compound of general formula (VII) 68 in which X has the meaning mentioned above, which is optionally isolated and / or optionally it is purified, and that is reacted with a optionally substituted phenylhydrazine of the general formula (VIII)

         \ vskip1.000000 \ baselineskip
      

69

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

or a corresponding salt of same, in which Y has the meaning according to one or more of the claims 1 or 2, under an inert atmosphere, to give a compound of general formula (IX)

         \ vskip1.000000 \ baselineskip
      

70

         \ vskip1.000000 \ baselineskip
      

         \ vskip1.000000 \ baselineskip
      

in which X and Y have the meaning mentioned above, which is optionally isolated and / or optionally purified, and optionally transferred under inert atmosphere to a compound of general formula (XI) through the reaction with an agent activating

         \ vskip1.000000 \ baselineskip
      

71

         \ newpage
      

in which the substituents X and Y they have the meaning mentioned above and A represents a leaving group, said compound being optionally isolated and / or optionally purified, and at least one compound of formula general (XI) is reacted with a compound of formulas general XII or XIIa 72 in which n, R 5, R 6, R 7 and R 8 are as defined in any of claims 1 or 2; under inert atmosphere to give a substituted pyrazoline compound of general formula I, which optionally it is isolated and / or optionally purify

         \ vskip1.000000 \ baselineskip
      

23. Medication comprising at least one substituted pyrazoline compound of general formula I according to claims 1 to 21, and optionally one or more excipients pharmaceutically acceptable. 24. Use of at least one pyrazoline compound substituted according to one or more of claims 1 to 21, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a drug for the modulation of cannabinoid receptors, preferably receptors of cannabinoids 1 (CB1), for prophylaxis and / or treatment of disorders of the central nervous system, disorders of the system immune, cardiovascular system disorders, disorders of the endocrine system, respiratory system disorders, disorders of the gastrointestinal tract or reproductive disorders. 25. Use of at least one pyrazoline compound substituted according to one or more of claims 1 to 21, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or the treatment of eating disorders, preferably bulimia, anorexia, cachexia, obesity and / or diabetes Type II mellitus (non-insulin dependent diabetes mellitus), plus preferably obesity. 26. Use of at least one pyrazoline compound substituted according to one or more of claims 1 to 21, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or the Psychosis treatment. 27. Use of at least one pyrazoline compound substituted according to one or more of claims 1 to 21, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or the treatment of alcoholism and / or alcohol addiction, abuse of nicotine and / or smoking, drug abuse and / or drug addiction and / or abuse of drugs and / or drug dependence, preferably drug abuse and / or drug addiction and / or abuse of nicotine and / or smoking. 28. Use of at least one pyrazoline compound substituted according to one or more of claims 1 to 21, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or the treatment of one or more types of cancers selected from the group which consists of brain cancer, bone cancer, lip cancer, mouth cancer, esophageal cancer, stomach cancer, cancer liver, bladder cancer, pancreas cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, skin cancer, colon cancer, intestinal cancer and prostate cancer, more preferably for the prophylaxis and / or treatment of one or more types of cancers selected from the group consisting of cancer of colon, bowel cancer and prostate cancer. 29. Use of at least one pyrazoline compound substituted according to one or more of claims 1 to 21, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medication for prophylaxis and / or the treatment of one or more of the disorders selected from the group consisting of bone disorders, preferably osteoporosis (by example, osteoporosis associated with a genetic predisposition, deficit of sex hormones or aging), bone disease associated with cancer or bone disease of Paget; schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, disorders Cognitive, cranial trauma, craniocerebral trauma, stroke, panic attacks, neuropathy peripheral, inflammation, glaucoma, migraine, Parkinson's disease,  Huntington's disease, Alzheimer's disease, Raynaud, tremors, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, medication-induced movement disorders, dystonia, endotoxemic shock, hemorrhagic shock, hypotension, insomnia, immunological disorders, sclera plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic analgesics and not narcotics, or to influence intestinal transit.